Accelerate healthcare and life sciences AI 
with NVIDIA and Nebius

Nebius gives scientific AI teams the infrastructure to move from research to production — running NVIDIA BioNeMo Agent Toolkit and NVIDIA Nemotron™ natively, validated against NVIDIA’s Cloud Partner Reference Architecture, for agentic drug discovery, genomics and clinical AI at scale.

Live healthcare agents already in production, backed by NVIDIA Exemplar Cloud status.

Nebius, validated by NVIDIA

Nebius operates one of the largest independent AI clouds purpose-built for training and inference at scale. That scale carries NVIDIA’s own validation: Preferred Cloud Partner and Reference Platform NVIDIA Cloud Partner status, verified through strict adherence to NVIDIA’s Cloud Partner Reference Architecture.

In healthcare and life sciences, that shows up as the first BioNeMo integration on Nebius and the BioNeMo Agent Toolkit workshop at GTC Berlin — Nebius infrastructure NVIDIA stands behind.

Built for the rigor of scientific AI

Nebius infrastructure, NVIDIA-validated

GPU clusters built and operated by Nebius, verified against the NVIDIA Cloud Partner Reference Architecture.

Compliance without compromise

Data residency and enterprise controls Nebius builds directly into pharma, biotech and healthcare workloads.

From framework to clinical workflow

Nebius Token Factory serves BioNeMo’s domain models in production, not just a notebook.

NVIDIA BioNeMo Agent Toolkit, running on Nebius

The BioNeMo Agent Toolkit packages a decade of NVIDIA life sciences libraries, open models and NIM microservices as skills any AI agent can call — so agents can gather evidence, run computational experiments and recommend next steps. Nebius is a launch AI cloud partner: deploy the toolkit’s NIM endpoints and serve its reasoning layer on Nebius infrastructure, from first notebook to production workflow.

Protein structure and design

Folding, de novo binder design and protein engineering skills, GPU-accelerated end to end.

Chemistry and docking

Generative chemistry, molecular docking and virtual screening as callable agent skills.

Genomics and biomarkers

Parabricks-accelerated genomic analysis and biomarker discovery in the agent’s reasoning loop.

57% → 100%

agent task completion with BioNeMo skills

2x

more passing assertions per 1,000 tokens

50+

companies already building with the toolkit

Webinar series: AI agents for life sciences

A webinar series with NVIDIA and J.P. Morgan on building AI agents for life sciences — from the BioNeMo Agent Toolkit fundamentals to production deployment on Nebius.

Session 1 · On demand

Build AI agents for life sciences with NVIDIA BioNeMo and Nebius, in partnership with J.P. Morgan

What the BioNeMo Agent Toolkit is and how it works, how to deploy and scale it on Nebius AI Cloud, and where startups can apply agentic AI across R&D.

Speakers: Ilya Burkov, Laura Boykin Okalebo, René Schönfelder (Nebius) · Elizabeth Scallon, Mahan Salehi, Chelsea Sumner (NVIDIA) · Jun Deng (J.P. Morgan)

Session 2 · On demand

Building and Evaluating Clinical Speech AI with NVIDIA, Nebius and J.P.Morgan

Explore how NVIDIA’s open models can power ambient-care and clinical voice-agent workflows. A practical walkthrough of deploying Nemotron Speech on Nebius, adapting it to medical vocabulary and evaluating its accuracy and safety for clinical use.

Speakers: Ilya Burkov, Laura Boykin Okalebo, Rene Schonfelder, Elizabeth Scallon, Jun Deng.

NVIDIA Nemotron on Nebius Token Factory

Nebius Token Factory runs NVIDIA Nemotron as the reasoning and orchestration layer under any BioNeMo-built agent: fine-tune on your own clinical data, then serve it with dedicated endpoints and per-token pricing — no separate infrastructure to stand up.

In the press

NVIDIA press release, June 23, 2026

NVIDIA names Nebius a launch AI cloud partner for the BioNeMo Agent Toolkit.

Customer story

Prima Mente Decodes Brain Signals With AI Foundation Models.

Ready to build your next healthcare AI breakthrough on Nebius?

Find us at NVIDIA GTC Washington, D.C., Nov 30–Dec 3, 2026.